Astria Therapeutics, Inc. Clinical Trials

Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.

2026-04-21: Study NCT07635095; Company role Lead sponsor; Phase Phase 1; Status Recruiting.
2025-10-01: Study NCT07204938; Company role Lead sponsor; Phase Phase 3; Status Enrolling by invitation.
2025-03-20: Study NCT06842823; Company role Lead sponsor; Phase Phase 3; Status Active not recruiting.
2025-01-07: Study NCT06782477; Company role Lead sponsor; Phase Phase 1; Status Active not recruiting.

Start date	Study	Company role	Phase	Status	Conditions	Enrollment	Completion date
2026-04-21	NCT07635095 A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants	Lead sponsor	Phase 1	Recruiting	Healthy Adult Participants	180	2026-12
2025-10-01	NCT07204938 A Long-Term Study of Navenibart in Participants With Hereditary Angioedema	Lead sponsor	Phase 3	Enrolling by invitation	Hereditary Angioedema (HAE)	145	2031-12
2025-03-20	NCT06842823 A Study of Navenibart in Participants With Hereditary Angioedema	Lead sponsor	Phase 3	Active not recruiting	Hereditary Angioedema (HAE)	157	2027-06
2025-01-07	NCT06782477 A Study of STAR-0310 in Healthy Adult Participants	Lead sponsor	Phase 1	Active not recruiting	Healthy Participants	40	2026-01
2023-09-26	NCT06007677 A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema	Lead sponsor	Phase 2	Active not recruiting	Hereditary Angioedema	56	2031-03
2023-02-21	NCT05695248 A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema	Lead sponsor	Phase 1, Phase 2	Completed Results posted	Hereditary Angioedema	29	2025-03-13
2022-07-27	NCT05477160 A Study of STAR-0215 in Healthy Adult Participants	Lead sponsor	Phase 1	Completed	Hereditary Angioedema	41	2023-11-17